Ardent Health's revenue stability at ~$1.6B masks significant earnings volatility, with operating margin compressing to 2.7% in 2026Q2 from 8.3% a year earlier and EPS falling 77% YoY to $0.12. The company's balance sheet has strengthened, with debt-to-equity ...
Price trend, volume and key moving averages
Trailing total returns as of 10/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | $0.12-34.0% vs $0.18 | $1.6B+2.0% vs $1.6B |
Q2 2026 May 5, 2026 | $0.28+55.6% vs $0.18 | $1.6B+1.5% vs $1.6B |
Q2 2026 Mar 4, 2026 | $0.32-8.0% vs $0.35 | $1.6B-1.6% vs $1.6B |
Q4 2025 Nov 12, 2025 | $0.52+22.6% vs $0.42 | $1.6B+1.8% vs $1.5B |
Shares of Ardent Health, Inc. (NYSE: ARDT - Get Free Report) have received an average recommendation of "Hold" from the fifteen brokerages that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and seven have assigned a buy recommendation to the company.
Investors need to pay close attention to ARDT stock based on the movements in the options market lately.
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that 13 hospitals across its network earned recognition in U.S. News & World Report's 2026-2027 Best Hospitals rankings, the publication's 37th annual assessment of hospital quality. The honors include a Best Regional Hospital designation, regional specialty rankings and 34 High Performing ratings across procedures and conditi.
Hsbc Holdings PLC bought a new position in Ardent Health, Inc. (NYSE: ARDT) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 55,280 shares of the company's stock, valued at approximately $543,000. A number of other institutional investors and hedge
Benchmark ARDT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Ardent Health Inc. (ARDT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.25 | $1.47B | 10.68 | 6.01% | 2.15% | 8.47% | — | |
| $423.39 | $91.66B | 14.92 | 7.08% | 8.77% | — | — | |
| $253.97 | $21.88B | 16.40 | 3.12% | 10.27% | 25.45% | — | |
| $2.75 | $387.77M | 0.73 | -1.18% | -1.34% | — | — | |
| $175.07 | $10.6B | 7.58 | 9.71% | 8.42% | 20.37% | — | |
| $169.63 | $9.89B | 29.05 | 18.72% | 6.9% | 16.51% | — |
Ardent Health Inc. (ARDT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Ardent Health Inc. (ARDT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Jun 30, 2026·SEC
Jun 2, 2026·SEC
Get notified when ARDT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Ardent Health Inc. (ARDT) stock FAQ — growth, dividends, profitability & financials explained
Ardent Health Inc. (ARDT) reported $6.41B in revenue for fiscal year 2025. This represents a 204% increase from $2.11B in 2016.
Ardent Health Inc. (ARDT) grew revenue by 6.0% over the past year. This is steady growth.
Yes, Ardent Health Inc. (ARDT) is profitable, generating $78.2M in net income for fiscal year 2025 (2.1% net margin).
Ardent Health Inc. (ARDT) has a return on equity (ROE) of 8.5%. This is below average, suggesting room for improvement.
Ardent Health Inc. (ARDT) generated $300.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
